Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer

References

• Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;29:2705–12.
   Google Scholar
• Yuasa Y. Epigenetics in molecular epidemiology of cancer a new scope. Adv Genet 2010;71:211–35.
   Google Scholar
• Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14: R65–R76.
   PubMed Web of Science ®Google Scholar
• Jo UH, Whang YM, Sung JS, Kim YH. Methylation of AKAP12{alpha} promoter in lung cancer. Anticancer Res 2010;30:4595–600.
   Google Scholar
• Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129–39.
   Google Scholar
• Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of Sparc in ovarian cancer. Neoplasia 2009;11: 126–35.
   PubMed Web of Science ®Google Scholar
• Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 2009;45:1129–36.
   PubMed Web of Science ®Google Scholar
• Furtado YL, Almeida G, Lattario F, Silva KS, Maldonado P, Silveira FA, do Val IC, Fonseca R, Carvalho Mda G. The presence of methylation of the p16INK4A gene and human papillomavirus in high-grade cervical squamous intraepithelial lesions. Diagn Mol Pathol 2010;19:15–9.
   Google Scholar
• Goto T, Mizukami H, Shirahata A, Yokomizo K, Kitamura YH, Sakuraba K, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. Anticancer Res 2010;30:2701–3.
   Google Scholar
• Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S. Carcinoma of the ovary. Int J Gynecol Obstet 2003;83(Suppl. 1):135–66.
   Google Scholar
• Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827–31.
   PubMed Web of Science ®Google Scholar
• Surowiak P, Materna V, Maciejczyk A, Pudelko M, Suchocki S, Kedzia W, Nowak-Markwitz E, Dumanska M, Spaczynski M, Zabel M, Dietel M, Lage H. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol Histopathol 2008;23:531–8.
   Google Scholar
• Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006;107:299–308.
   PubMed Web of Science ®Google Scholar
• Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365–9.
   PubMed Web of Science ®Google Scholar
• Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002;8:3324–31.
   PubMed Web of Science ®Google Scholar
• De Caceres II, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476–81.
   Google Scholar
• Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG Island Methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961–7.
   PubMed Web of Science ®Google Scholar
• McCluskey L, Chen C, Delgadillo E, Felix JC, Muderspach L, Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999;72:87–92.
   PubMed Web of Science ®Google Scholar
• Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P. CpG methylation analysis – current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 2009;11:266–78.
   PubMedGoogle Scholar
• Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of sodium bisulfite conversion and realtime PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209–17.
   PubMed Web of Science ®Google Scholar
• Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, Choi C, Fackler MJ, Sukumar S. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol 2010;118:176–81.
   Google Scholar
• Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001;158:1121–7.
   PubMed Web of Science ®Google Scholar
• Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988–93.
   PubMed Web of Science ®Google Scholar
• Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:210–8.
   PubMed Web of Science ®Google Scholar
• Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 2006;241: 213–20.
   Google Scholar
• Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:61–5.
   Google Scholar